We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
